Browse our 650+ Publications​

Latest Publications

Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma

Suvannasankha A, et al.
Cancer
August 2024
Authors and Affiliates
Attaya Suvannasankha MD1 | Nizar Bahlis MD2 | Suzanne Trudel MSc, MD3 | Katja Weisel MD4 | Christian Koenecke MD5 | Albert Oriol MD, PhD6 | Peter M. Voorhees MD7 | Aranzazu A. Alonso MD8 | Natalie S. Callander MD9 | María‐Victoria Mateos MD, PhD10 | Nishitha Reddy MD11 | Shawn Hakim PhD12 | John LaMacchia MD, PhD13 | Nashita Patel MSc, PhD14 | Danaé Williams MSc12 | Roxanne C. Jewell PhD15 | Xiangdong Zhou PhD12 | Ira Gupta MD16 | Joanna Opalinska MD12 | Ajay K. Nooka MD, MPH, FACP17 1 Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, Indiana, USA 2 Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada 3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada 4 University Medical Center Hamburg‐Eppendorf, Hamburg, Germany 5 Hannover Medical School, Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany 6 Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain 7 Levine Cancer Institute, Atrium Health/Wake Forest University School of Medicine, Charlotte, North Carolina, USA 8 Hospital Universitario Quirónsalud Madrid, Madrid, Spain 9 Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA 10Instituto de Investigación Biomédica de Salamanca and Centro de Investigación del Cáncer, Hospital Universitario de Salamanca, Salamanca, Spain 11Merck & Co., Inc, Rahway, New Jersey, USA 12GlaxoSmithKline, Upper Providence, Pennsylvania, USA 13GlaxoSmithKline, Waltham, Massachusetts, USA 14GlaxoSmithKline, Stevenage, UK 15GlaxoSmithKline, Durham, North Carolina, USA 16GlaxoSmithKline, Philadelphia, Pennsylvania, USA 17Winship Cancer Institute, Emory University Hospital, Atlanta, Georgia, USA

Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation

Schneider-Hohendorf, et al.
Brain
July 2024
Authors and Affiliates
Tilman Schneider-Hohendorf, Christian Wünsch, Simon Falk, Catarina Raposo, Florian Rubelt, Hamid Mirebrahim, Hosseinali Asgharian, Ulrich Schlecht, Daniel Mattox, Wenyu Zhou, Eva Dawin, Marc Pawlitzki, Sarah Lauks, Sven Jarius, Brigitte Wildemann, Joachim Havla, Tania Kümpfel, Miriam-Carolina Schrot, Marius Ringelstein, Markus Kraemer, Carolin Schwake, Thomas Schmitter, Ilya Ayzenberg, Katinka Fischer, Sven G. Meuth, Orhan Aktas, Martin W. Hümmert, Julian R. Kretschmer, Corinna Trebst, Ilka Kleffner, Jennifer Massey, Paolo A. Muraro, Haiyin Chen-Harris, Catharina C. Gross, Luisa Klotz, Heinz Wiendl and Nicholas Schwab

Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN

Chari A, et al.
Blood Cancer Journal
July 2024
Authors and Affiliates
Ajai Chari 1,22✉, Jonathan L. Kaufman 2, Jacob Laubach 3, Douglas W. Sborov4, Brandi Reeves 5, Cesar Rodriguez1, Rebecca Silbermann6, Luciano J. Costa 7, Larry D. Anderson Jr 8, Nitya Nathwani9, Nina Shah10, Naresh Bumma11, Sarah A. Holstein 12, Caitlin Costello13, Andrzej Jakubowiak 14, Tanya M. Wildes12, Robert Z. Orlowski 15, Kenneth H. Shain16, Andrew J. Cowan17, Huiling Pei18, Annelore Cortoos19, Sharmila Patel19, Thomas S. Lin19, Peter M. Voorhees 20✉, Saad Z. Usmani 21✉ and Paul G. Richardson 1Icahn School of Medicine at Mount Sinai, New York, NY, USA. 2Winship Cancer Institute, Emory University, Atlanta, GA, USA. 3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 4Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA. 5University of North Carolina–Department of Medicine–Chapel Hill, Chapel Hill, NC, USA. 6Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. 7University of Alabama at Birmingham, Birmingham, AL, USA. 8Myeloma, Waldenstrӧm’s and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA. 9Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 10University of California San Francisco, San Francisco, CA, USA. 11Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 12Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. 13Moores Cancer Center, University of California San Diego, La Jolla, CA, USA. 14University of Chicago Medical Center, Chicago, IL, USA. 15Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 16Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. 17Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA, USA. 18Janssen Research & Development, LLC, Titusville, NJ, USA. 19Janssen Scientific Affairs, LLC, Horsham, PA, USA. 20Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC, USA. 21Memorial Sloan Kettering Cancer Center, New York, NY, USA. 22Affiliation at the time of study conduct.

A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia

Srinagesh H, et al.
Blood
July 2024
Authors and Affiliates
Hrishikesh Srinagesh1 , Clayton Jackson2 , Parveen Shiraz3 , Nikeshan Jeyakumar1 , Mark Hamilton1 , Emily Egeler4 , Sharon Mavroukakis4 , Adam Kuo4 , Juancarlos Cancilla4 , Bita Sahaf4 , Neha Agarwal3 , Alyssa Kanegai3 , Anne Marijn Kramer3,4 , Sally Arai3 , Sushma Bharadwaj3 , Saurabh Dahiya3 , Hitomi Hosoya3 , Laura Johnston3 , Vanessa Kennedy3 , Michaela Liedtke1 , Robert Lowsky3 , Lekha Mikkilineni3 , Robert Negrin3 , Andrew Rezvani3 , Surbhi Sidana3 , Judith Shizuru3 , Melody Smith3 , Wen-Kai Weng3 , Steven Feldman4 , Matthew J. Frank3,4 , Zachary Lee5 , Mary Tagliaferri5 , A. Mario Marcondes5 , David Miklos3,4 , Crystal Mackall4 , Lori Muffly3,4 Division of Hematology/Oncology, UT Southwestern, Dallas, TX; 3 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford CA; 4 Center for Cancer Cell Therapy, Stanford University, Stanford, CA; 5 Nektar Therapeutics, San Francisco, CA

Molecular disease monitoring in patients with relapsed/refractory B-cell lymphoma receiving anti-CD19 CAR T-cell therapy

Colton M, et al.
Clinical Lymphoma Myeloma & Leukemia
June 2024
Authors and Affiliates
Colton, Meryl MD MSc1; Purev, Enkhtsetseg MD1; Haverkos, Bradley MD MPH1; Bair, Steven MD1; Jasem, Jagar MD MPH1; Allison Jacob MS2; Kamdar, Manali MD1 1. Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, CO 2. Adaptive Biotechnologies, Seattle WA

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma

Melani C, et al.
New England Journal of Medicine
June 2024
Authors and Affiliates
C. Melani, R. Lakhotia, S. Pittaluga, J.D. Phelan, D.W. Huang, G. Wright, J. Simard, J. Muppidi, C.J. Thomas, M. Ceribelli, F.A. Tosto, Y. Yang, W. Xu, T. Davies‑Hill, S.D. Pack, C.J. Peer, O. Arisa, E. Mena, L. Lindenberg, E. Bergvall, C.A. Portell, R.J. Farah, S.T. Lee, A. Pradhan, C. Morrison, A. Tadese, A.M. Juanitez, C. Lu, A. Jacob, H. Simmons, W.D. Figg, S.M. Steinberg, E.S. Jaffe, M. Roschewski, L.M. Staudt, and W.H. Wilson Lymphoid Malignancies Branch (C. Melani, R.L., J.D.P., D.W.H., J.S., J.M., Y.Y., W.X., A.P., C. Morrison, A.T., A.M.J., M.R., L.M.S., W.H.W.), the Clinical Pharmacology Program (C.J.P., O.A., W.D.F.), the Molecular Imaging Branch (E.M., L.L., E.B.), and the Biostatistics and Data Management Section (S.M.S.), Center for Cancer Research, the Laboratory of Pathology, Clinical Center (S.P., T.D.-H., S.D.P., E.S.J.), and the Biometric Research Program, Division of Cancer Treatment and Diagnosis (G.W.), National Cancer Institute, the Division of Pre-Clinical Innovation Chemistry Technologies, National Center for Advancing Translational Sciences (C.J.T., M.C., F.A.T.), and the Clinical Center Pharmacy Department (C.L.), National Institutes of Health, Bethesda, and Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore (S.T.L.) — all in Maryland; the Division of Hematology and Oncology, University of Virginia, Charlottesville (C.A.P.); Mario Lemieux Center for Blood Cancers, University of Pittsburgh School of Medicine, Pittsburgh (R.J.F.); and Adaptive Biotechnologies, Seattle (A.J., H.S.)

Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

Bumma N, et al.
Journal of Clinical Oncology
June 2024
Authors and Affiliates
Naresh Bumma, MD1; Joshua Richter, MD2 ; Sundar Jagannath, MD2 ; Hans C. Lee, MD3 ; James E. Hoffman, MD4; Attaya Suvannasankha, MD5 ; Jeffrey A. Zonder, MD6 ; Mansi R. Shah, MD7 ; Suzanne Lentzsch, MD, PhD8 ; Rachid Baz, MD9 ; Joseph J. Maly, MD10; Swathi Namburi, MD11; Matthew J. Pianko, MD12 ; Jing Christine Ye, MD, MS12; Ka Lung Wu, MD, PhD13 ; Rebecca Silbermann, MD14 ; Chang-Ki Min, MD15; Marie-Christiane Vekemans, MD16; Markus Munder, MD17 ; Ja Min Byun, MD18 ; Joaqu´ın Mart´ınez-Lopez, MD19 ; Kaniel Cassady, PhD20 ; Michelle DeVeaux, PhD20; Dhruti Chokshi, BS20; Anita Boyapati, PhD20; Anasuya Hazra, PhD20; George D. Yancopoulos, MD, PhD20; L. Andres Sirulnik, MD, PhD20; Karen Rodriguez Lorenc, MD20; Glenn S. Kroog, MD20 ; Yariv Houvras, MD, PhD20; and Madhav V. Dhodapkar, MD21 1The Ohio State University Comprehensive Cancer Center, Columbus, OH 2Icahn School of Medicine at Mount Sinai, New York, NY 3The University of Texas MD Anderson Cancer Centre, Houston, TX 4University of Miami Health System, Miami, FL 5Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN 6Karmanos Cancer Institute, Detroit, MI 7Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 8Columbia University Medical Center, New York, NY 9Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL 10Norton Cancer Institute, Louisville, KY 11Swedish Cancer Institute, Seattle, WA 12Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 13Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium 14Knight Cancer Institute, Oregon Health & Science University, Portland, OR 15Department of Hematology, College of Medicine, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea 16Department of Hematology, Cliniques Universitaires Saint-Luc, Universit´e Catholique de Louvain (UCLouvain), Brussels, Belgium 17Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany 18Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea 19Hospital 12 de Octubre, i112, School of Medicine Universidad Complutense, CNIO, Madrid, Spain 20Regeneron Pharmaceuticals, Inc, Tarrytown, NY 21Emory University School of Medicine, Atlanta, GA

Fixed-Duration Pirtobrutinib plus Venetoclax with or without Rituximab inRelapsed/Refractory CLL: Phase 1b BRUIN Trial

Roeker L, et al.
Blood
June 2024
Authors and Affiliates
Lindsey E. Roeker1, Jennifer A. Woyach2, Chan Y. Cheah3, Catherine C. Coombs4, Nirav N. Shah5, William G. Wierda6, Manish R. Patel7, Nicole Lamanna8, Donald E. Tsai9, Binoj Nair9, Chunxiao Wang10, Xiang Zhao9, Dan Liu10, David Radtke10, Sonya Chapman10, Narasimha Marella9, Samuel C. McNeely9, Jennifer R. Brown11 1Memorial Sloan Kettering Cancer Center, New York, NY, USA 2The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA 3Linear Clinical Research, and Sir Charles Gairdner Hospital, and the University of Western Australia, Perth, Australia 4University of California, Irvine, Orange, CA, USA 5Medical College of Wisconsin, Milwaukee, WI, USA 6MD Anderson Cancer Center, Houston, TX, USA 7Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA 8Columbia University Medical Center/New York-Presbyterian, New York, NY, USA 9Loxo@Lilly, Indianapolis, IN, USA 10Eli Lilly and Company, Indianapolis, IN, USA 11Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
Previous Next